Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-11-17

Clinical Trial Update: A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

A completed Phase 3 trial evaluating the usability of a subcutaneous auto-injector for CT-P17 in patients with active rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CT-P17 (adalimumab biosimilar)

Snippet

Sponsor: Celltrion | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2021-11-17